Journal for ImmunoTherapy of Cancer (Nov 2021)
886 Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures
Abstract
No abstracts available.